Immunotherapy

1. Gene symbol

 

2. Response

Combined response (n=1,434)

3. Treatment

Anti PD-1 (CD279) therapy

any anti PD-1

nivolumab

pembrolizumab

Anti PD-L1 (CD274) therapy

any anti PD-L1

atezolizumab

durvalumab

Anti CTLA4 (CD152) therapy

any anti CTLA-4

ipilimumab

Any

any immune checkpoint inhibitor therapy

Total: 0

Non-responders: 0

Responders: 0

4. Filters (optional)

Sample acquisition All Pretreatment(n = 1267) Ontreatment (n = 167)

Gender All Male (n = 801) Female (n = 350)

Primary tumor All No (n = 164) Yes (n = 552)

Metastatic All No (n = 120) Yes (n = 988)

5. Settings

Tissue of origin Non Small Cell Lung Cancer Glioblastoma Ureter/ Renal Pelvis Gastric Cancer Colorectal Urothelial Melanoma Bladder Hepatocellular Carcinoma Non Squamous Lung Cancer Small Cell Lung Cancer Esophageal Adeno Breast Renal Cell Carcinoma Squamous Lung Cancer Head And Neck Squamous Cell Carcinoma All

No outliers

Show quartiles

Multi-gene analysis

Calculate

By using the services, you agree to be bound by the Terms of Use.

Please kindly cite our paper to support further development: Kovacs SA, Fekete JT, Gyorffy B.: Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors , Acta Pharmacol Sin., 2023 Apr 13.;doi: 10.1038/s41401-023-01079-6.